Navigation Links
Doctors Test Advanced Tool for Treating Prostate Cancer
Date:10/27/2008

Technology Designed to Confirm Precise Brachytherapy Treatment

ST. LOUIS, Oct. 27 /PRNewswire/ -- Leading radiation oncologists are using the TargetScan Touch(TM) system to deliver radioactive seed therapy in the prostate. The innovative technology is based on a motionless probe which stabilizes the prostate during procedures. With the gland stabilized, physicians use a touch-screen interface and 3-D ultrasound images to map and confirm placement of radiation.

Unveiled recently at the 2008 American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting, the TargetScan Touch(TM) has been tested at several of the nation's leading medical centers, including Emory University School of Medicine.

"This technology delivers two important benefits. First, a stabilized prostate; second, the ability to quickly and efficiently image anywhere in the prostate with the point and click function for accurate positioning of radioactivity," explains Peter Rossi, M.D., Emory's assistant professor in the departments of radiation oncology and urology. "TargetScan has a short learning curve for my residents and physicists and has demonstrated its value in that we have consistently achieved quality implants with its help."

Just launched, the system will initially be in clinical use at Emory, Washington University Medical Center in St. Louis, University of Florida and New Hanover Radiation Oncology.

The system is based on the TargetScan(R) technology platform developed by Envisioneering Medical Technologies in St. Louis, under the guidance of physicians at Washington University. "Traditional hand-manipulated devices allow the prostate gland to shift, which impedes placement accuracy. By stabilizing the prostate, physicians can now implant seeds to any and every region of the gland with greater confidence," said Robert Mills, president, Envisioneering Medical Technologies.

Other system features include intuitive imaging and navigational controls and a compact, streamlined system design to enhance treatment efficiency, improve the patient experience and provide ease of transport for physicians managing multiple practice locations.

"The design of TargetScan Touch(TM) is straightforward to support ease of use and widespread adoption so that physicians and their patients can benefit from this new technology," added Mills. "The simplicity of the touch-screen technology saves time while producing detailed images and treatment reports for future patient monitoring."

TargetScan Touch Technical Features:

-- Motionless probe to prevent prostate movement and on-screen image distortion.

-- Mapping technology for complete prostatic coverage, assisting with accurate needle placement to pre-planned cancer targets and preferred treatment zones.

-- 3-D image acquisition to improve visibility, presenting both sagittal and transverse planes with a total viewing volume of 380 mL.

-- Touch-screen technology to improve treatment efficiency and patient experience.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated to creating the standard for prostate cancer care by developing technology for improving prostate cancer diagnosis and treatment precision and effectively managing patients throughout the continuum of care. For more information please visit http://www.envisioneeringmedical.com.


'/>"/>
SOURCE Envisioneering Medical Technologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation
2. Doctors Lack Smoking Cessation Training
3. Doctors Often Overestimate Patients Health Literacy
4. MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource
5. Research suggests doctors should consider kidney-sparing surgery
6. Will patients stick to physical therapy? Questionnaire can help doctors predict
7. Help for Stutterers on The Doctors TV Show Presented by Power Stuttering Center Founder Mark Power
8. Maternity Care Doctors to Call for Renewal of MCARE Abatement Fund, Address Growing Shortage of Maternity Care Physicians
9. For Some Doctors, Empathy Is in Short Supply
10. Many Doctors Dont Know Blood Pressure Guidelines
11. UC Davis doctors use multimedia to increase colorectal cancer screening among Hispanics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Georgia (PRWEB) , ... May 26, 2016 , ... ... certificate in intellectual property (IP) to its specialty academic programs. , Answering to ... the college’s existing certificate programs in health law, and environmental and land use ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... ... 26, 2016 , ... Nike Yoga Camps at East West ... arts & crafts, discussions, and games all geared towards enhancing your child’s physical ... backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. Nike ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology: